Movement Alert｜BIOCYTOGEN-B Falls 6.31% in Regular Trading, Biotech Sector Selloff Ahead of Earnings Release

Market Focus08-24

On August 24, BIOCYTOGEN-B fell 6.31% in regular trading, trading at 61.1 HKD/share, with turnover of 25.44 million HKD.

On the news front, the company's interim results are scheduled for release on August 27. While the company previously pre-announced H1 attributable net profit growth of 392% to 413% year-on-year, reaching 236.1 million to 246.1 million yuan, some institutional views have turned cautious on the near-term outlook, citing a lack of clear revenue guidance and consensus estimates for the current quarter.

Simultaneously, the broader biotechnology sector came under significant selling pressure. Within the sector, AKESO fell 1.44%, INNOVENT BIO declined 3.12%, BEONE MEDICINES dropped 3.51%, and CANSINOBIO lost 4.14%, with sector-wide linkage effects amplifying adjustment pressure on individual stocks including BIOCYTOGEN-B.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137034710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-24 10:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137034710","market":"us","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Falls 6.31% in Regular Trading, Biotech Sector Selloff Ahead of Earnings Release","media":"Market Focus","content":"<p><p>On August 24, BIOCYTOGEN-B fell 6.31% in regular trading, trading at 61.1 HKD/share, with turnover of 25.44 million HKD.</p><p>On the news front, the company's interim results are scheduled for release on August 27. While the company previously pre-announced H1 attributable net profit growth of 392% to 413% year-on-year, reaching 236.1 million to 246.1 million yuan, some institutional views have turned cautious on the near-term outlook, citing a lack of clear revenue guidance and consensus estimates for the current quarter.</p><p>Simultaneously, the broader biotechnology sector came under significant selling pressure. Within the sector, AKESO fell 1.44%, INNOVENT BIO declined 3.12%, BEONE MEDICINES dropped 3.51%, and CANSINOBIO lost 4.14%, with sector-wide linkage effects amplifying adjustment pressure on individual stocks including BIOCYTOGEN-B.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Falls 6.31% in Regular Trading, Biotech Sector Selloff Ahead of Earnings Release</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Falls 6.31% in Regular Trading, Biotech Sector Selloff Ahead of Earnings Release\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-24 10:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 24, BIOCYTOGEN-B fell 6.31% in regular trading, trading at 61.1 HKD/share, with turnover of 25.44 million HKD.</p><p>On the news front, the company's interim results are scheduled for release on August 27. While the company previously pre-announced H1 attributable net profit growth of 392% to 413% year-on-year, reaching 236.1 million to 246.1 million yuan, some institutional views have turned cautious on the near-term outlook, citing a lack of clear revenue guidance and consensus estimates for the current quarter.</p><p>Simultaneously, the broader biotechnology sector came under significant selling pressure. Within the sector, AKESO fell 1.44%, INNOVENT BIO declined 3.12%, BEONE MEDICINES dropped 3.51%, and CANSINOBIO lost 4.14%, with sector-wide linkage effects amplifying adjustment pressure on individual stocks including BIOCYTOGEN-B.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1137034710","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137034710","pubTimestamp":1787539487,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 24, BIOCYTOGEN-B fell 6.31% in regular trading, trading at 61.1 HKD/share, with turnover of 25.44 million HKD.On the news front, the company's interim results are scheduled for release on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势警报|BIOCYTOGEN-B 常规交易中下跌 6.31%，生物技术板块在财报发布前遭遇抛售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On August 24, BIOCYTOGEN-B fell 6.31% in regular trading, trading at 61.1 HKD/share, with turnover of 25.44 million HKD.On the news front, the company's interim results are scheduled for release on August 27. While the company previously pre-announced H1 attributable net profit growth of 392% to 413% year-on-year, reaching 236.1 million to 246.1 million yuan, some institutional views have turned cautious on the near-term outlook, citing a lack of clear revenue guidance and consensus estimates for the current quarter.Simultaneously, the broader biotechnology sector came under significant selling pressure. Within the sector, AKESO fell 1.44%, INNOVENT BIO declined 3.12%, BEONE MEDICINES dropped 3.51%, and CANSINOBIO lost 4.14%, with sector-wide linkage effects amplifying adjustment pressure on individual stocks including BIOCYTOGEN-B.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137034710","isCrawlerRequest":true}